Department of Medicine, Institute for Molecular Medicine, and Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia 23298, USA.
Clin Cancer Res. 2010 Jan 15;16(2):376-83. doi: 10.1158/1078-0432.CCR-09-1029. Epub 2010 Jan 12.
The DNA damage response (DDR) represents a complex network of multiple signaling pathways involving cell cycle checkpoints, DNA repair, transcriptional programs, and apoptosis, through which cells maintain genomic integrity following various endogenous (metabolic) or environmental stresses. In cancer treatment, the DDR occurs in response to various genotoxic insults by diverse cytotoxic agents and radiation, representing an important mechanism limiting chemotherapeutic and radiotherapeutic efficacy. This has prompted the development of agents targeting DDR signaling pathways, particularly checkpoint kinase 1 (Chk1), which contributes to all currently defined cell cycle checkpoints, including G1/S, intra-S-phase, G2/M, and the mitotic spindle checkpoint. Although numerous agents have been developed with the primary goal of enhancing the activity of DNA-damaging agents or radiation, the therapeutic outcome of this strategy remains to be determined. Recently, new insights into DDR signaling pathways support the notion that Chk1 represents a core component central to the entire DDR, including direct involvement in DNA repair and apoptotic events in addition to checkpoint regulation. Together, these new insights into the role of Chk1 in the DDR machinery could provide an opportunity for novel approaches to the development of Chk1 inhibitor strategies.
DNA 损伤反应 (DDR) 代表了一个涉及细胞周期检查点、DNA 修复、转录程序和细胞凋亡的复杂的多个信号通路网络,通过该网络,细胞可以在各种内源性(代谢)或环境压力后维持基因组完整性。在癌症治疗中,DDR 会对各种细胞毒性药物和辐射引起的各种遗传毒性损伤作出反应,这是限制化疗和放疗疗效的一个重要机制。这促使人们开发针对 DDR 信号通路的药物,特别是检查点激酶 1(Chk1),它有助于所有目前定义的细胞周期检查点,包括 G1/S、S 期内、G2/M 和有丝分裂纺锤体检查点。尽管已经开发了许多药物,其主要目的是增强 DNA 损伤药物或辐射的活性,但这种策略的治疗效果仍有待确定。最近,对 DDR 信号通路的新认识支持了 Chk1 代表整个 DDR 的核心组成部分的观点,包括除了检查点调节之外,还直接参与 DNA 修复和细胞凋亡事件。总之,这些关于 Chk1 在 DDR 机制中的作用的新认识为开发 Chk1 抑制剂策略提供了一个新的机会。